Literature DB >> 23269583

Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia.

Ayda Bennour1, Ines Ouahchi, Bechir Achour, Monia Zaier, Yosra Ben Youssef, Abderrahim Khelif, Ali Saad, Halima Sennana.   

Abstract

The Philadelphia chromosome (Ph) derives from the balanced translocation between chromosomes 9 and 22. This chromosomal translocation results in the fusion between the 5' part of the BCR gene, normally located on chromosome 22, and the 3' part of the ABL gene on chromosome 9 giving origin to a BCR-ABL fusion gene which is transcribed and then translated into a hybrid protein. In general, three breakpoint cluster regions in the BCR gene have been described: major (M-BCR), minor (m-BCR) and micro (μ-BCR). Three main variants of the BCR-ABL gene have been described depending on the length of the sequence of the BCR gene included that encode for the P190, P210, P230 proteins. Most patients (95 %) were found to have P210 protein that resulted from rearrangement in the M-BCR region in the BCR gene and thus gives rise to b2a2 or b3a2 variants. The incidence of one or other rearrangement in chronic myeloid leukemia (CML) patients varies in different reported series. These two variants are associated with distinct clinical types of human leukemias. In this study, we report the frequencies of M-BCR-ABL fusion transcripts in 44 CML patients and we review the data on the correlations between the type of M-BCR/ABL variant and the corresponding sex, age and biological features. Forty-four untreated chronic phase CML patients were studied. The type of BCR-ABL fusion transcripts was determined by reverse transcriptase polymerase chain reaction (RT-PCR). More than half of them showed b3a2 fusion transcript (64 %), while (36 %) showed b2a2 transcript. No patients coexpressed b3a2/b2a2. Correlation between biological data demonstrated that: (a) M-BCR rearrangements were not associated with the sex of the patients. (b) Patients with b3a2 rearrangements were older than patients with b2a2 transcripts. (c) M-BCR rearrangements were influenced neither by the white blood count (WBC) nor with hemoglobin levels. However, platelet level is more elevated in patients with b3a2 transcript (681.2/L vs. 207/L; P = 0.001). In conclusion, we observed significant correlations between age, platelet level and M-BCR-ABL transcript, these observations deserve further investigations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23269583     DOI: 10.1007/s12032-012-0348-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  48 in total

1.  Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)

Authors:  F Pane; F Frigeri; M Sindona; L Luciano; F Ferrara; R Cimino; G Meloni; G Saglio; F Salvatore; B Rotoli
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

2.  Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival.

Authors:  P Shepherd; R Suffolk; J Halsey; N Allan
Journal:  Br J Haematol       Date:  1995-03       Impact factor: 6.998

3.  Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction.

Authors:  M S Lee; A LeMaistre; H M Kantarjian; M Talpaz; E J Freireich; J M Trujillo; S A Stass
Journal:  Blood       Date:  1989-06       Impact factor: 22.113

4.  E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib.

Authors:  Ayda Bennour; Nathalie Beaufils; Halima Sennana; Balkis Meddeb; Ali Saad; Jean Gabert
Journal:  J Clin Pathol       Date:  2010-08       Impact factor: 3.411

Review 5.  Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia.

Authors:  J J van Dongen; E A Macintyre; J A Gabert; E Delabesse; V Rossi; G Saglio; E Gottardi; A Rambaldi; G Dotti; F Griesinger; A Parreira; P Gameiro; M G Diáz; M Malec; A W Langerak; J F San Miguel; A Biondi
Journal:  Leukemia       Date:  1999-12       Impact factor: 11.528

6.  Relationship of bcr breakpoint to chronic phase duration, survival, and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase.

Authors:  S W Morris; L Daniel; C M Ahmed; A Elias; P Lebowitz
Journal:  Blood       Date:  1990-05-15       Impact factor: 22.113

7.  The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia.

Authors:  A Eisenberg; R Silver; L Soper; Z Arlin; M Coleman; B Bernhardt; P Benn
Journal:  Leukemia       Date:  1988-10       Impact factor: 11.528

8.  Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia.

Authors:  Marjan Yaghmaie; Seyed H Ghaffari; Ardashir Ghavamzadeh; Kamran Alimoghaddam; Mohammad Jahani; Seyed-Asadollah Mousavi; Masoud Irvani; Babak Bahar; Isa Bibordi
Journal:  Arch Iran Med       Date:  2008-05       Impact factor: 1.354

9.  Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.

Authors:  J Groffen; J R Stephenson; N Heisterkamp; A de Klein; C R Bartram; G Grosveld
Journal:  Cell       Date:  1984-01       Impact factor: 41.582

10.  Long term follow up after allogeneic stem cell transplantation for chronic myelogenous leukemia.

Authors:  E Reiter; H T Greinix; S Brugger; F Keil; W Rabitsch; C Mannhalter; I Schwarzinger; P Höcker; G Fischer; K Dieckmann; W Hinterberger; W Linkesch; B Schneider; K Lechner; P Kalhs
Journal:  Bone Marrow Transplant       Date:  1998-12       Impact factor: 5.483

View more
  7 in total

1.  Is the BCR-ABL1 transcript type in chronic myeloid leukaemia relevant?

Authors:  Stephen E Langabeer
Journal:  Med Oncol       Date:  2013-02-21       Impact factor: 3.064

2.  Prevalence of Abelson murine leukemia viral oncogene homolog-breakpoint cluster region fusions and correlation with peripheral blood parameters in chronic myelogenous leukemia patients in Lorestan Province, Iran.

Authors:  Ali Asghar Kiani; Farhad Shahsavar; Mojtaba Gorji; Kolsoum Ahmadi; Vahideh Heydari Nazarabad; Banafsheh Bahmani
Journal:  Int J Appl Basic Med Res       Date:  2016 Oct-Dec

3.  Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia.

Authors:  Graeme Greenfield; Ross McMullan; Nuala Robson; Julie McGimpsey; Mark Catherwood; Mary Frances McMullin
Journal:  BMC Hematol       Date:  2019-05-02

4.  Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase?

Authors:  T P de Almeida Filho; P A Maia Filho; Maritza Cavalcante Barbosa; Luana Letícia Alves Dutra; Marilena Facundo de Castro; Fernando Barroso Duarte; Acy Telles de Souza Quixadá; Romélia Pinheiro Gonçalves Lemes
Journal:  Hematol Transfus Cell Ther       Date:  2019-02-16

5.  Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients.

Authors:  Mahmood S Khazaal; Farqad B Hamdan; Qasim S Al-Mayah
Journal:  Mol Genet Genomic Med       Date:  2019-06-17       Impact factor: 2.183

6.  BCR-ABL fusion genes and laboratory findings in patients with chronic myeloid leukemia in northeast Iran.

Authors:  Hossein Ayatollahi; Mohammad Reza Keramati; Abbas Shirdel; Mohammad Mehdi Kooshyar; Majid Raiszadeh; Sepideh Shakeri; Mohammad Hadi Sadeghian
Journal:  Caspian J Intern Med       Date:  2018

Review 7.  Prognostic Significance of Transcript-Type BCR - ABL1 in Chronic Myeloid Leukemia.

Authors:  Matteo Molica; Elisabetta Abruzzese; Massimo Breccia
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-09-01       Impact factor: 2.576

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.